Surrogate Markers of Disease Studied as Means of Determining AIDS Drugs' Effectiveness

Paul Cotton
JAMA. 1990;264(18):2362-2365. doi:10.1001/jama.1990.03450180012002.
Text Size: A A A
Published online


ENOUGH EVIDENCE may exist to approve two analogues of zidovudine ([AZT] Retrovir, Burroughs Wellcome, Research Triangle Park, NC).

At issue is whether surrogate markers of disease progression, like CD4 cell counts, can substitute for clinical end points like death.

If so, data from ongoing trials might be collated into a convincing case. If not, it could be 2 years or more before traditional criteria are met.

The drugs ddC (dideoxycytidine, Hoffmann-LaRoche Inc, Nutley, NJ) and ddI (didanosine [formerly called dideoxyinosine], Bristol-Myers Squibb Company, Princeton, NJ) inhibit viral replication as does zidovudine, which is still the only licensed drug that fights the human immunodeficiency virus (HIV) linked with the acquired immunodeficiency syndrome (AIDS).

"Preliminary data show clear-cut drug activity," says Margaret Fischl, MD, who studies all three drugs as an investigator for the National Institutes of Health (Bethesda, Md) AIDS Clinical Trials Group.

All three can cause peripheral neuropathy. But ddI


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.